Key result
Targeting the first stem-loop (SL1) of the SARS-CoV-2 leader with an antisense oligo efficiently and specifically down-regulated SARS-CoV-2 mRNA by blocking NSP1-mediated viral evasion.
Why the study?
Conflicting reports existed regarding the mechanisms by which SARS-CoV-2 viral mRNAs overcome NSP1-mediated host translation inhibition to avoid silencing.
Identification of specific residues in SARS-CoV-2 SL1 and NSP1 required for viral evasion provides potential new drug targets, such as ASOs against SL1.
SL1 ASOs merit preclinical antiviral testing; animal data leave open human translation and efficacy.
SARS-CoV-2, responsible for the ongoing global pandemic, must overcome a conundrum faced by all viruses. To achieve its own replication and spread, it simultaneously depends on and subverts cellular mechanisms. At the early stage of infection, SARS-CoV-2 expresses the viral nonstructural protein 1 (NSP1), which inhibits host translation by blocking the mRNA entry tunnel on the ribosome; this interferes with the binding of cellular mRNAs to the ribosome. Viral mRNAs, on the other hand, overcome this blockade. We show that NSP1 enhances expression of mRNAs containing the SARS-CoV-2 leader. The first stem-loop (SL1) in the viral leader is both necessary and sufficient for this enhancement mechanism. Our analysis pinpoints specific residues within SL1 (three cytosine residues at the positions 15, 19, and 20) and another within NSP1 (R124), which are required for viral evasion, and thus might present promising drug targets. We target SL1 with the antisense oligo (ASO) to efficiently and specifically down-regulate SARS-CoV-2 mRNA. Additionally, we carried out analysis of a functional interactome of NSP1 using BioID and identified components of antiviral defense pathways. Our analysis therefore suggests a mechanism by which NSP1 inhibits the expression of host genes while enhancing that of viral RNA. This analysis helps reconcile conflicting reports in the literature regarding the mechanisms by which the virus avoids NSP1 silencing.
No takes yet. Share an insight, caveat, or question.
Bujanic et al. (2022) studied SARS-CoV-2 infection. Antisense oligo (ASO) targeting SL1 was evaluated on Down-regulation of SARS-CoV-2 mRNA. Targeting the first stem-loop (SL1) of the SARS-CoV-2 leader with an antisense oligo efficiently and specifically down-regulated SARS-CoV-2 mRNA by blocking NSP1-mediated viral evasion.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: